Sinopia Biosciences
Sinopia Biosciences, a San Diego-based company, is revolutionizing drug discovery with data-driven, high-throughput multi-omics and machine learning.
- 8
- Private company
- San Diego, CA, USUnited States
Sinopia Biosciences, a San Diego-based company, is revolutionizing drug discovery with data-driven, high-throughput multi-omics and machine learning.
sinopiabio.comCrawled Oct 15, 2026
Advances in omics technologies allow comprehensive, cost-effective measurement of biomolecules across entire cellular systems. In drug discovery, this means that phenotypes are no longer defined by a few markers, but by quantitative changes in hundreds of thousands of cellular features.
The company aims to transform the treatment of complex diseases using discoveries enabled by artificial intelligence and omics data. It develops deep learning algorithms to analyze biological data and identify therapeutic targets and drug candidates.
Sinopia Biosciences receives a **$2.5 million NIH NIGMS SBIR Phase II grant** to develop an **AI-powered metabolomics foundation model** for drug discovery. The model integrates metabolomics data via Sinopia’s **LEADS® platform** to accelerate therapeutic insights. The funding supports further refinement of the platform’s capabilities in unifying fragmented metabolomics datasets.
Oct 2026Sinopia BiosciencesNews article
Sinopia’s research demonstrates a small molecule that improves Parkinson’s disease treatment efficacy. The findings, published in *Science Translational Medicine*, highlight a potential advancement in therapeutic approaches for neurodegenerative disorders. The study builds on prior work to refine drug mechanisms targeting motor symptoms.
Oct 2026Sinopia BiosciencesNews article
Sinopia Biosciences reports preclinical data showing **SB-0110**, a novel PKA-II modulator, improves motor function in Parkinson’s disease models when combined with levodopa. Non-human primate studies demonstrate reduced dyskinesia while maintaining therapeutic benefit. The candidate is advancing through late-stage toxicology toward its first-in-human trial.
Jul 2026Sinopia BiosciencesNews article
Sinopia Bio secures seed financing to advance its lead program targeting Parkinson’s disease. The company develops Eli, a drug candidate entering clinical trials. Researchers focus on addressing neurodegenerative symptoms through novel mechanisms.
Jul 2026Sinopia BiosciencesNews article